Ind-Swift Laboratories Past Earnings Performance
Past criteria checks 4/6
Ind-Swift Laboratories has been growing earnings at an average annual rate of 53.2%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 11.5% per year. Ind-Swift Laboratories's return on equity is 5.9%, and it has net margins of 3.6%.
Key information
53.2%
Earnings growth rate
51.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.5% |
| Return on equity | 5.9% |
| Net Margin | 3.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ind-Swift Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12,004 | 432 | 1,534 | 0 |
| 30 Sep 23 | 12,256 | 513 | 1,495 | 0 |
| 30 Jun 23 | 12,375 | 450 | 1,410 | 0 |
| 31 Mar 23 | 12,159 | 476 | 1,401 | 0 |
| 31 Dec 22 | 12,231 | 113 | 1,279 | 0 |
| 30 Sep 22 | 11,571 | -2 | 1,234 | 0 |
| 30 Jun 22 | 10,691 | -11 | 1,164 | 0 |
| 31 Mar 22 | 10,529 | -21 | 1,278 | 0 |
| 31 Dec 21 | 9,754 | 301 | 1,163 | 0 |
| 30 Sep 21 | 9,555 | 256 | 1,144 | 0 |
| 30 Jun 21 | 9,536 | 111 | 1,130 | 0 |
| 31 Mar 21 | 9,068 | -31 | 1,079 | 0 |
| 31 Dec 20 | 8,776 | 277 | 1,097 | 0 |
| 30 Sep 20 | 8,536 | 77 | 1,082 | 0 |
| 30 Jun 20 | 8,360 | -111 | 1,022 | 0 |
| 31 Mar 20 | 7,993 | -212 | 1,058 | 0 |
| 31 Dec 19 | 7,977 | -734 | 1,021 | 0 |
| 30 Sep 19 | 7,992 | -211 | 1,012 | 0 |
| 30 Jun 19 | 7,872 | -35 | 929 | 0 |
| 31 Mar 19 | 7,790 | 289 | 1,018 | 0 |
| 31 Mar 18 | 7,769 | 220 | 963 | 0 |
| 31 Mar 17 | 7,142 | -391 | 765 | 0 |
| 31 Mar 16 | 6,641 | -587 | 694 | 0 |
| 31 Mar 15 | 6,778 | -1,194 | 571 | 0 |
| 31 Mar 14 | 9,738 | -1,220 | 867 | 78 |
Quality Earnings: 532305 has a large one-off loss of ₹277.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 532305's current net profit margins (3.6%) are higher than last year (0.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532305 has become profitable over the past 5 years, growing earnings by 53.2% per year.
Accelerating Growth: 532305's earnings growth over the past year (283.4%) exceeds its 5-year average (53.2% per year).
Earnings vs Industry: 532305 earnings growth over the past year (283.4%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 532305's Return on Equity (5.9%) is considered low.